We are live on ! Find out more
PTIXW

Protagenic Therapeutics Warrant
PTIXW

Delisted

PTIXW was delisted on the 2nd of January, 2026.

Back to rankings

1 hedge funds and large institutions have $5.32K invested in Protagenic Therapeutics Warrant in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.26% less ownership

Funds ownership: 4.35% → 4.09% (-0.26%)

16% less capital invested

Capital invested by funds: $6.32K → $5.32K (-$999)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$379
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$5.32K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
– -$379 -11,327 Closed

PTIXW Hedge Fund Activity: Q3 2023 in Review

1 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q3 2023, worth a combined $5.32K — down 16% from $6.32K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $379 sold.

  • 1 institutional investor held Protagenic Therapeutics Warrant (PTIXW) as of Q3 2023, down from 2 in Q2 2023.
  • Funds reported $5.32K of Protagenic Therapeutics Warrant stock for Q3 2023, down 16% quarter-over-quarter.
  • 0 funds opened new Protagenic Therapeutics Warrant positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Protagenic Therapeutics Warrant seller in Q3 2023 was Susquehanna International Group, an estimated $379 sold.

Based on aggregated 13F filings for Q3 2023.